The role of nuclear medicine in monitoring treatment in skeletal malignancy
- 1 July 2001
- journal article
- review article
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 31 (3) , 206-211
- https://doi.org/10.1053/snuc.2001.23527
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.Journal of Clinical Oncology, 1998
- Advanced breast cancer: use of resources and cost implicationsBritish Journal of Cancer, 1993
- Leuprolide Therapy for Prostate Cancer An Association with Scintigraphic “Flare” on Bone ScanClinical Nuclear Medicine, 1990
- Bone scans with one or two new abnormalities in cancer patients with no known metastases: frequency and serial scintigraphic behavior of benign and malignant lesions.Radiology, 1990
- The clinical course of bone metastases from breast cancerBritish Journal of Cancer, 1987
- THE ASSESSMENT OF RESPONSE TO THERAPY OF BONE METASTASES IN BREAST CANCERAustralian and New Zealand Journal of Medicine, 1984
- Osseous metastases of breast cancer. Clinical, biochemical, radiographic, and scintigraphic evaluation of response to therapyCancer, 1984
- Assessment of response of bone metastases to systemic treatment in patients with breast cancerCancer, 1983
- Assessment of progression of secondary bone lesions following cancer of the breast or prostate using serial radionuclide imagingThe British Journal of Radiology, 1981
- Assessment of response to therapy in advanced breast cancerPublished by Elsevier ,1977